+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Cancer Drugs Market, by Drugs, Cancer, Therapy, and Companies

  • ID: 4607567
  • Report
  • August 2018
  • Region: China
  • 102 pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Celegene
  • Eli Lilly
  • Merck
  • Roche
  • Sino BioPharma
  • MORE
Anti-Cancer drugs are the drugs which are used to reduce or prevent the cell proliferation of cancerous tissues. China Cancer Drugs Market is projected to reach US$ 30 Billion by the year 2024; owing to the increasing prevalence of various types of cancer, changing lifestyle & dietary habits, growing aging population, rising demand of targeted drug therapy and the patent expiration of key cancer drugs. Cancer is one of the leading causes of death worldwide and is a major public health burden in both developed and developing countries.

The rate of cancer incidences in China is exploding very rapidly; nearly 4 million people diagnosed and almost 3 million died from it. For instance; due to increasing air pollution over the last couple of years, lung cancer has increased 50% in Beijing only. Anticancer drugs act like an inhibitor that prevents cancer cells to grow.

In addition; factors like growing awareness regarding cancer diagnosis & treatment, advancement in cancer drugs and therapies, rise in cancer awareness programs like breast cancer screening, investment in healthcare infrastructure are expected to drive China anti-cancer drugs market positively over the forecast period. However, major side-effects of cancer drugs and its high cost are certainly restraining the China anti-cancer drugs market to reach its full potential.

This report titled “China Cancer Drugs Market, by Drugs [Cytotoxic Drugs (Antimetabolities, Plant Alkaloids, Alkylating Agents), Targeted Drugs, Monoclonal Antibiotics, Hormonal Drugs, Traditional Chinese Medicine (TCM), & Others], Cancer (Lung, Stomach, Breast, Esophageal, Liver & Others), Therapy (Chemotherapy, Targeted Therapy, Hormonal Therapy & Others), Companies (Merck, Celgene, Eli Lilly, Roche & Sino BioPharma)” provides a complete analysis of China Anti-Cancer Drugs Market.

By Drugs - Cytotoxic Drugs leads the Cancer Drugs Market in China

Based on the drugs type, China cancer drugs market is segmented into cytotoxic drugs, targeted drugs, Monoclonal Antibiotics, hormonal drugs, TCM and Others. The cytotoxic drugs segment is further classified into Antimetabolites, Plant Alkaloids and Alkylating Agents.

By Cancer - Lungs Cancer accounts for the largest share of China Cancer Drugs Market

On the basis of cancer type, China cancer drugs market is segmented into Lung, Stomach, Breast, Esophageal, Liver & Others. Lung, Breast and Stomach Cancer dominates the China anti-cancer drugs market and is expected to do so in the near future.

By Therapy - Targeted Therapy is expected to grow significantly during the forecast period

By therapy type, the China anti-cancer drugs market is segmented into chemotherapy, targeted therapy, hormonal therapy and others. Chemotherapy and targeted therapy together held the major share of China cancer drugs market.

Company Analysis

Some of the prominent companies competing in the China Anti-Cancer Drugs Market, and profiled in the report include Merck, Celegene, Eli Lilly, Roche and Sino BioPharma.

This market research report provides a complete analysis of the China Cancer Drugs Market, Growth Drivers, Challenges, and their projections for the upcoming years.

By Drugs
  • Cytotoxic Drugs
  • Antimetabolities
  • Plant Alkaloids
  • Alkylating Agents
  • Targeted Drugs
  • Monoclonal Antibiotics
  • Hormonal Drugs
  • Traditional Chinese Medicine (TCM)
  • Others
By Cancer
  • Lung Cancer
  • Stomach Cancer
  • Breast Cancer
  • Esophageal Cancer
  • Liver Cancer
  • Others
By Therapy
  • Chemotherapy
  • Targeted Therapy
  • Hormonal Therapy
  • Others
Companies Covered in the Report
  • Merck
  • Celegene
  • Eli Lilly
  • Roche
  • Sino BioPharma
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celegene
  • Eli Lilly
  • Merck
  • Roche
  • Sino BioPharma
  • MORE
1. Executive Summary

2. China Cancer Drugs Market

3. Market Share - China Anti - Cancer Drugs
3.1 By Drugs
3.2 By Cancer
3.3 By Therapy

4. Drugs - China Cancer Market
4.1 Cytotoxic Drugs
4.1.1 Antimetabolities
4.1.2 Plant Alkaloids
4.1.3 Alkylating Agents
4.2 Targeted Drugs
4.3 Monoclonal Antibiotics
4.4 Hormonal Drugs
4.5 Traditional Chinese Medicine (TCM)
4.6 Others

5. Cancer Type - Market
5.1 Lung Cancer
5.2 Stomach Cancer
5.3 Breast Cancer
5.4 Esophageal Cancer
5.5 Liver Cancer
5.6 Others

6. Therapy - China Cancer Market
6.1 Chemotherapy
6.2 Targeted Therapy
6.3 Hormonal Therapy
6.4 Others

7. Company Analysis
7.1 Merck
7.1.1 Company Overview
7.1.2 Financial Insights
7.2 Celgene
7.2.1 Company Overview
7.2.2 Financial Insights
7.3 Eli Lilly
7.3.1 Company Overview
7.3.2 Financial Insights
7.4 Roche
7.4.1 Company Overview
7.4.2 Financial Insights
7.5 Sino BioPharma
7.5.1 Company Overview
7.5.2 Financial Insights

8. Growth Drivers
8.1 Growing Awareness towards Cancer Diagnosis and Treatment
8.2 Increasing Use of Targeted Therapy
8.3 Increasing Research and Development Activities
8.4 Cutting Import Duties on Cancer Drugs

9. Challenges
9.1 High Cost of Cancer Drugs
9.2 Major Side Effects of Cancer Treatment

List of Figures
Figure 2 - 1: China - Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 2 - 2: China - Forecast for Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 3 - 1: By Drugs - China Anti - Cancer Drugs Market Share (%), 2011 - 2017
Figure 3 - 2: By Drugs - Forecast for China Anti - Cancer Drugs Market Share (%), 2018 - 2024
Figure 3 - 3: By Cancer - China Anti - Cancer Drugs Market Share (%), 2011 - 2017
Figure 3 - 4: By Cancer - Forecast for China Anti - Cancer Drugs Market Share (%), 2018 - 2024
Figure 3 - 5: By Therapy - China Anti - Cancer Drugs Market Share (%), 2011 - 2017
Figure 3 - 6: By Therapy - Forecast for China Anti - Cancer Drugs Market Share (%), 2018 - 2024
Figure 4 - 1: Cytotoxic Drugs - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 4 - 2: Cytotoxic Drugs - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 4 - 3: Antimetaboloties - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 4 - 4: Antimetaboloties - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 4 - 5: Plant Alkaloids - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 4 - 6: Plant Alkaloids - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 4 - 7: Alkylating Agents - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 4 - 8: Alkylating Agents - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 4 - 9: Targeted Drugs - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 4 - 10: Targeted Drugs - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 4 - 11: Monoclonal Antibiotics - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 4 - 12: Monoclonal Antibiotics - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 4 - 13: Hormonal Drugs - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 4 - 14: Hormonal Drugs - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 4 - 15: Traditional Chinese Medicine (TCM) - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 4 - 16: Traditional Chinese Medicine (TCM) - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 4 - 17: Others - China Anti - Cancer Drugs Market (Million US$), 2011 - 2017
Figure 4 - 18: Others - Forecast for China Anti - Cancer Drugs Market (Million US$), 2018 - 2024
Figure 5 - 1: Lung Cancer - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 5 - 2: Lung Cancer - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 5 - 3: Stomach Cancer - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 5 - 4: Stomach Cancer - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 5 - 5: Breast Cancer - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 5 - 6: Breast Cancer - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 5 - 7: Esophageal Cancer - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 5 - 8: Esophageal Cancer - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 5 - 9: Liver Cancer - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 5 - 10: Liver Cancer - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 5 - 11: Others - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 5 - 12: Others - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 6 - 1: Chemotherapy - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 6 - 2: Chemotherapy - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 6 - 3: Targeted Therapy - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 6 - 4: Targeted Therapy - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 6 - 5: Hormonal Therapy - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 6 - 6: Hormonal Therapy - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 6 - 7: Others - China Anti - Cancer Drugs Market (Billion US$), 2011 - 2017
Figure 6 - 8: Others - Forecast for China Anti - Cancer Drugs Market (Billion US$), 2018 - 2024
Figure 7 - 1: Merck - Global Oncology Product Sales (Million US$), 2011 - 2017
Figure 7 - 2: Merck - Forecast for Global Oncology Product Sales (Million US$), 2018 - 2024
Figure 7 - 3: Celgene - Global Net Product Sales (Million US$), 2011 - 2017
Figure 7 - 4: Celgene - Forecast for Global Net Product Sales (Million US$), 2018 - 2024
Figure 7 - 5: Eli Lilly - Global Oncology Revenue (Million US$), 2011 - 2017
Figure 7 - 6: Eli Lilly - Forecast for Global Oncology Revenue (Million US$), 2018 - 2024
Figure 7 - 7: Roche - Global Oncology Products Sales (Million US$), 2011 - 2017
Figure 7 - 8: Roche - Forecast for Global Oncology Products Sales (Million US$), 2018 - 2024
Figure 7 - 9: Sino BioPharma - Global Oncology Revenue (Million US$), 2012 - 2017
Figure 7 - 10: Sino BioPharma - Forecast for Global Oncology Revenue (Million US$), 2018 - 2024
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Merck
  • Celegene
  • Eli Lilly
  • Roche
  • Sino BioPharma
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll